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Abstract
Background: Acute kidney injury (AKI) occurs commonly in the setting of orthotopic liver transplantation (OLT). To
date, the correlation between AKI post-OLT and pre-operative changes in renal function has not been rigorously
examined.
Methods: To determine the impact of pre-OLT changes in renal function on AKI post-OLT, as well as to identify
risk factors for AKI, we analyzed the prospectively maintained NIDDK Liver Transplantation Database, which includes
patients who received their first OLT between April 15, 1990, and June 30, 1994. We used the AKI Network
definition of AKI.
Results: Surprisingly, univariate analysis revealed that worsening renal function while awaiting OLT was protective
to the development of AKI post-OLT. Independent predictors of AKI were increased body mass index, increased
Childs-Pugh-Turcott score, decreased urine output during cross-clamp, improved renal function while awaiting OLT,
increased post-operative stroke volume, non-Caucasian race, and post-operative use of tacrolimus.
Conclusions: The correlation between improving renal function pre-OLT and AKI post-OLT may represent true
protection (via ischemic pre-conditioning) or, alternatively, a masking of milder forms of AKI (via improved renal
perfusion through correction of the cirrhotic milieu). These results highlight the complex interaction between liver
and kidney disease, and suggest that not only the etiology but also the course of pre-OLT renal dysfunction may
be a critical determinant of renal function post-OLT.
Background
Acute kidney injury (AKI) occurs commonly in the set-
ting of orthotopic liver transplantation (OLT). The inci-
dence varies widely, from 12% to 80%, depending on the
definition of AKI [1-4]. While awaiting OLT, patients
often develop varying degrees of renal impairment, ran-
ging from prerenal azotemia to hepatorenal syndrome
and acute tubular necrosis. Although a majority of stu-
dies has identified a pre-operative elevation of serum
creatinine (SCr) as a risk factor for the development of
AKI post-OLT, the timing and definition of AKI have
been imprecise and inconsistent [1,4-6].
Transient changes of SCr in patients awaiting OLT
most often occurs as a result of changes in renal perfu-
sion. These changes, which are attributable to events
and/or interventions such as large-volume paracentesis,
diuretic therapy, sepsis, or gastrointestinal bleeding, tend
to reduce the predictive power of pre-OLT SCr [7,8]. To
date, the correlation between the development of AKI
post-OLT and pre-operative changes in renal function,
as assessed by SCr, blood urea nitrogen (BUN), or esti-
mated glomerular filtration rate (eGFR), has not been
rigorously examined.
To determine the impact of pre-OLT changes in SCr,
BUN, and eGFR on development of AKI post-OLT, as
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any medium, provided the original work is properly cited.well as to identify additional potential risk factors for
AKI, we performed an analysis of the prospectively
maintained National Institute of Diabetes and Digestive
and Kidney Diseases (NIDDK) Liver Transplantation
Database (LTD) [9]. Given the previous lack of consis-
tency among studies in terms of criteria and timing of
AKI, we used the Acute Kidney Injury Network (AKIN)
definition of AKI [10].
Methods
Study population
The NIDDK-LTD was established to study the demo-
graphics, clinical and laboratory characteristics, and out-
comes of patients evaluated for and undergoing OLT.
The NIDDK-LTD contains extensive pre- and post-OLT
data for 916 recipients from 3 clinical centers: Mayo
Clinic, Rochester, Minnesota; University of Nebraska
Medical Center, Omaha, Nebraska; and University of
California, San Francisco, California. The NIDDK-LTD
is maintained by the Epidemiology Data Coordinating
C e n t e ra tt h eU n i v e r s i t yo fP i t t s b u r g hG r a d u a t eS c h o o l
of Public Health. Data collection for the NIDDK-LTD
was conducted under protocols approved by the Com-
mittees on Human Research at all three participating
clinical centers. Patient recruitment, which began on
April 15, 1990, and ended on June 30, 1994, included all
patients who received their first OLT during this inter-
val. Prospective data on patients were collected using
standardized data collection forms at initial evaluation,
OLT, and regular intervals post-OLT. Information on
the specific data collected from each patient has been
published previously [9]. Although data were obtained
during the 1990’s, the range and depth of these prospec-
tively obtained data still offer important clinical and
pathophysiologic insight into the development and risk
factors of AKI in patients with severe liver disease
undergoing OLT.
T h ec u r r e n ts t u d yw a sd e s i g n e da sar e t r o s p e c t i v e
cohort study. Of 916 patients enrolled in the NIDDK-
LTD, 688 patients were included in our analysis. We
excluded 228 patients for the following reasons: age <
18 years (n = 138); organ transplantation in addition to
OLT (n = 26); incomplete data (n = 5); and requirement
for renal replacement therapy (RRT) at registration, dur-
ing OLT, or on first day post-OLT (n = 59). Patients in
the last category were excluded because the onset of
AKI was felt to precede the peri-OLT period.
Definitions
In accord with AKIN recommendations, we defined AKI
as a reduction of renal function (occurring within 48
hours), manifesting by either an absolute increase of
SCr ≥ 0 . 3m g / d Lo rap e r c e n t a g ei n c r e a s eo fS C r≥
150%. The last pre-OLT SCr was used as baseline. eGFR
was determined using the 4-variable equation of the
Modification of Diet in Renal Disease (MDRD) study
group [11]. As urine output was only measured during
the intra-operative period, we did not use urine output
in defining AKI because of the unavailability of these
data in the NIDDK-LTD database. Absolute changes of
SCr (ΔScr), BUN (ΔBUN), and eGFR (ΔeGFR) were cal-
culated as pre-OLT minus registration values. Percent
changes of SCr (% ΔSCr), BUN (% ΔBUN), and eGFR
(% ΔeGFR) were calculated by the following formula: %
Δ = (pre-OLT value/registration value)-1 × 100%. Rates
of change of SCr (ΔSCr/Δtwait), BUN (ΔBUN/Δtwait),
and eGFR (ΔeGFR/Δtwait) were calculated by the follow-
ing formula: rate of change = absolute change/wait list
time.
Data collection
Pre-OLT data included routine demographic variables
(age, sex, race), admission physiologic variables (com-
plete blood count, electrolytes, clotting times, albumin,
liver enzymes, total bilirubin, body surface area (BSA]),
body mass index (BMI]), medications, comorbidities,
MELD (Model for End-Stage Liver Disease) and Childs-
Pugh-Turcott scores, and renal variables (registration
and pre-OLT values of BUN, SCr, and eGFR; ΔSCr,
ΔBUN, and ΔeGFR; % ΔSCr, % ΔBUN, and % ΔeGFR;
ΔSCr/Δtwait, ΔBUN/Δtwait,a n dΔeGFR/Δtwait;a n d
125I-
iodothalamate clearance at registration). BMI was calcu-
lated at the time of registration using actual body
weight, including ascites, by the following formula:
weight (kg) ÷ height (meters)
2.
Peri- and intra-operative data included surgical and
cross-clamp times; use of veno-veno bypass; administra-
tion of blood products (packed red blood cells [PRBC],
platelets, fresh frozen plasma [FFP], cryoprecipitate, and
colloid solutions); and hemodynamic variables (heart
rate, mean arterial pressure [MAP], central venous pres-
sure [CVP], mean pulmonary artery pressure [MPAP],
pulmonary artery wedge pressure [PAWP], cardiac out-
put [CO], stroke volume [SV], and systemic vascular
resistance [SVR]; and urine output. Hemodynamic vari-
ables and urine output were determined at the start of
surgery, during cross-clamp (anhepatic phase) and fol-
lowing cross-clamp (reperfusion phase).
Data analysis
The primary outcome was development of AKI. As the
number of patients with AKI stage 2 and stage 3 (AKI-2
and AKI-3) was too small for meaningful analysis (45 and
20 patients, respectively), all statistical analyses unless
otherwise indicated were performed for patients who
developed AKI (AKI) vs. those who did not (NO AKI).
Summary statistics were computed for both the AKI
and NO AKI cohorts. Continuous variables were
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by Student t test or Wilcoxon rank-sum test. Categorical
v a r i a b l e sw e r ec o m p a r e db yF i s h e r ’se x a c tt e s to rc h i -
square analysis. Comparison of cohorts included both
univariate and multivariate analysis. Variables significant
by univariate analysis at p < 0.05 were candidates for
multivariate analysis. We performed logistic regression
analysis with forward variable selection to determine
variables independently predictive of AKI. Stepwise
selections for logistic regression were based on the max-
imum likelihood ratio. For continuous variables, the
odds ratio (OR) represents the relative amount by which
the probability of obtaining the outcome variable
increases or decreases if the independent variable is
increased by exactly one unit. OR and their 95% confi-
dence intervals (CI) were determined by exponentiation
of the regression coefficient or its upper and lower 95%
CI, respectively.
Results
Univariate analyses of non-renal-function-associated risk
factors for AKI post-OLT
To determine factors correlating with AKI following
OLT, we analyzed multiple routinely available demo-
graphic, clinical, and laboratory variables obtained dur-
ing the pre-, intra- and post (first 48 hours)-operative
periods for 916 OLT recipients registered in the
NIDDK-LTD.
A total of 688 patients were evaluated, of whom 243
(35%) developed AKI. Of these, 178 (73%) developed
AKI-1, 45 (18%) AKI-2, and 20 (8%) AKI-3. 6 patients
(all with AKI-3) required RRT. We compared patients
who developed AKI (AKI) with those who did not (NO
AKI) by univariate analysis for multiple characteristics,
including pre-operative factors (Table 1), associated co-
morbidities (Table 2), therapeutic interventions (Table
3), peri-operative urine outputs and operative variables
(Table 4), and intra-operative hemodynamic variables
(Table 5).
The following pre-operative variables were signifi-
cantly associated with the development of AKI (Table
1): male sex (p = 0.02), non-Caucasian race (p = 0.035),
increased BSA (p < 0.00001), increased BMI (p <
0.00001), decreased platelet count (p < 0.00001), ele-
vated prothrombin time (p < 0.00001), elevated partial
thromboplastin time (p = 0.003), decreased serum albu-
min (p < 0.00007), and decreased serum sodium (p =
0.0005).
The following diagnoses and co-morbidities were sig-
nificantly associated with the development of AKI
(Table 2): Childs Pugh Turcott score (p = 0.00001),
ascites while awaiting OLT (p = 0.04) or at time of OLT
(p = 0.010), post-OLT mechanical ventilation (p <
0.00001), porto-systemic encephalopathy (p < 0.00001),
alcoholic liver disease (p = 0.048), chronic hepatitis (p =
0.04), and non-alcoholic steatohepatitis (p < 0.0001).
Therapeutic interventions associated with the develop-
ment of AKI included (Table 3): post-OLT use of loop
diuretic (p = 0.001) or tacrolimus (p < 0.0001); intra-
operative administration of PRBC (p = 0.003), platelets
(p = 0.0002), or FFP (p < 0.00002); lack of veno-venous
bypass (p = 0.044); and lack of cyclosporine (p = 0.001).
Intra-operative urine output differed significantly for
AKI patients only during cross-clamp, during which
they had a decreased urine flow (p < 0.00001) (Table 4).
The duration of cross-clamp was shorter in AKI patients
(p = 0.004). This may reflect a decreased use of venove-
nous bypass in AKI patients (Table 3), since cross-
clamp times were longer in AKI patients, when stratified
according to use of venoveno bypass (p < 0.0001, not
shown).
Hemodynamic variables were assessed at start of sur-
gery, during cross-clamp, and after cross-clamp (Table
5). At start of surgery, AKI patients had increased CO
(p < 0.00001), increased SV (p < 0.00001), and decreased
SVR (p < 0.00002). During cross-clamp, AKI patients
had higher heart rates (p = 0.001) and higher MAP
(0.043). Finally, following release of cross-clamp, AKI
patients had increased CO (p < 0.00001), increased SV
(p < 0.00003), and decreased SVR (p < 0.00003).
Univariate analyses of pre-OLT measures of renal function
as risk factors for AKI post-OLT
To determine the impact of renal function on develop-
ment of AKI post-OLT, we evaluated multiple absolute
measures of renal function obtained at registration or
Table 1 Univariate analysis of demographic and pre-
operative variables in patients with and without AKI
No AKI (n = 445) AKI (n = 243) p value
Age 48.7 ± 11.3 50 ± 10.2 0.19
Sex (male) 232 (52%) 160 (66%) 0.02
Race (Caucasian) 369 (82%) 185 (76%) 0.035
BSA (m
2) 2.10 ± 0.30 2.26 ± 0.22 0.00001
BMI (kg/m
2 ) 25.3 ± 4.4 28 ± 5.8 0.00001
Hgb (g/dL) 11.1 ± 1.9 11.0 ± 1.9 0.76
WBC x10
9/L 6.4 ± 4.5 6.1 ± 3.4 0.61
Platelets x10
9/L 137 ± 135 104 ± 67 0.00001
PT (sec) 14.9 ± 4.7 15.0 ± 2.5 0.00001
PTT (sec) 37.3 ± 12.4 40 ± 13.7 0.003
Na (mmol/L) 136 ± 5.3 135 ± 5.9 0.0005
HCO3 (mmol/L) 23.7 ± 3.7 24 ± 4 0.12
AST (U/L) 133 ± 144 130 ± 125 0.60
ALT (U/L) 94 ± 144 85 ± 94 0.40
Total bilirubin (mg/dL) 6.7 ± 9 7 ± 10 0.07
Albumin (g/dL) 3.1 ± 0.6 2.87 ± 0.64 0.00007
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renal function while awaiting OLT (Table 6). No corre-
lation existed between AKI post-OLT and absolute
values of SCr, BUN, and eGFR, either at registration or
pre-OLT.
Unexpectedly, univariate analysis revealed an inverse
relationship between improving renal function while
awaiting OLT and development of AKI post-OLT. On
average, AKI patients had a greater degree of renal func-
tional preservation, or even improvement, while awaiting
OLT than did NO AKI patients. Thus, AKI post-OLT
was significantly correlated with a decreased ΔSCr, a
decreased % ΔSCr, and a decreased ΔSCr/Δtwait (ΔSCr =
0.036 ± 0.390 vs. 0.13 ± 0.70 mg/dL, p = 0.017; % ΔSCr
= 9 ± 40% vs. 19 ± 67%, p = 0.014; and ΔSCr/Δtwait =
-0.0014 ± 0.015 vs. 0.004 ± 0.034 mg/dL/day, p =
0.007). Similarly, the development of AKI was signifi-
cantly correlated with a decreased ΔeGFR, a decreased
% ΔeGFR, and a decreased ΔeGFR/Δtwait (ΔeGFR = -2.6
± 31 vs. -7.4 ± 26 ml/min, p = 0.021; % ΔeGFR = -3.7 ±
45% vs. 3.3 ± 38%, p = 0.014; and ΔeGFR/Δtwait =
-0.0014 ± 0.015 vs. 0.004 ± 0.034 ml/min/day, p =
0.007).
Multivariate analysis of risk factors for AKI post-OLT
We used forward stepwise logistic regression analysis to
determine which variables identified by univariate ana-
lyses (Tables 1, 2, 3, 4, 5, 6) were independent
predictors of AKI post-OLT (Table 7). Independent pre-
dictors of AKI, in descending order of coefficient of
determination, were increased BMI, increased Childs-
Pugh-Turcott score, decreased urine output during
cross-clamp, improved renal function while awaiting
OLT, increased post-OLT SV, non-Caucasian race, and
post-OLT use of tacrolimus.
Categorical analysis of effect of changes in renal function
while awaiting OLT on post-operative AKI
The emergence of improved renal function as an inde-
pendent risk factor for AKI post-OLT was unantici-
pated. To confirm the impact of pre-operative changes
of renal function on AKI post-OLT, we performed sev-
eral additional analyses. In the first, we subdivided
patients into those whose renal function remained the
same or declined while awaiting OLT vs. those whose
renal function improved (Table 8). AKI occurred in 42%
of patients whose eGFR improved vs. 32% of those
whose eGFR remained the same or decreased (p =
0.014, OR = 1.53, 95% CI = 1.10-2.20). A similar trend
was observed in comparing patients whose SCr
increased vs. those whose SCr remained the same or
decreased, although the difference did not achieve statis-
tical significance (38% vs. 32%, p = 0.11, OR = 1.30, 95%
CI = 0.95-1.80).
In the second analysis, we subdivided patients accord-
ing to ΔSCr/Δtwait (Figure 1). Negative values of ΔSCr/
Table 2 Univariate analysis of co-morbidities, hepatic diagnoses, and complications in patients with and without AKI
NO AKI (n = 445) AKI (n = 243) p value
Registration co-morbidities
Coronary artery disease 15 (3%) 11 (4%) 0.52
Diabetes 64 (14%) 31 (13%) 0.64
Hypertension 69 (16%) 45 (19%) 0.33
Hepatic disease leading to transplant
Alcoholic liver disease 81 (18%) 60 (25%) 0.048
Chronic hepatitis 162 (36%) 108 (44%) 0.041
Hepatitis B 28 (6%) 17 (7%) 0.74
Hepatitis C 63 (15%) 42 (18%) 0.31
Non-alcoholic steatohepatitis 160 (36%) 52 (21%) 0.00001
Complications while on waiting list
Ascites (registration) 325 (73%) 195 (82%) 0.04
Ascites (pre-operative) 289 (65%) 181(74%) 0.01
Variceal bleed (any time) 142 (32%) 70(29%) 0.40
Porto-systemic shunt (any time) 33 (7%) 24 (10%) 0.26
Bacterial peritonitis (any time) 59 (13%) 44 (17%) 0.09
Porto-systemic encephalopathy (any time) 195 (44%) 141 (58%) 0.00001
MELD score 15.7 ± 6 15.8 ± 5 0.8
Child-Pugh-Turcott score 8.4 ± 1.6 9.1 ± 1.5 0.00001
Other
Mechanical ventilation (post-operative) 271 (61%) 171 (70%) 0.00001
Retransplant 26 (6%) 24 (10%) 0.06
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OLT, whereas positive values indicate worsened renal
function. In general, for those deciles of ΔSCr/Δtwait
corresponding to improved renal function (ΔSCr/Δtwait
< 0), an increased percentage of patients developed AKI.
The opposite trend was observed for those deciles
corresponding to stable or worsening renal function
(ΔSCr/Δtwait ≥ 0). The inverse relationship between
degree of renal functional improvement and risk for
AKI was statistically significant (p = 0.008).
Finally, we repeated our analysis including the 11
patients who required RRT on the first day post-OLT.
These patients were excluded because the onset of their
AKI was felt to precede the peri-OLT period and there-
fore to be independent of operative factors. It is possible,
however, that their exclusion may have led to an under-
representation of patients with declining renal function
while awaiting OLT. Notably, even upon inclusion of
these patients, a significant correlation still existed
between the development of AKI and the same pre-OLT
renal functional variables: namely, decreased ΔSCr and %
ΔSCr; decreased ΔeGFR and % ΔeGFR; decreased ΔSCr/
Δt and ΔeGFR/Δt (Additional file 1, Table S1).
Table 3 Univariate analysis of effect of therapeutic
interventions in patients with and without AKI
NO AKI
(n = 445)
AKI
(n = 243)
p value
Wait list (any time)
Aminoglycoside 55 (12%) 24 (10%) 0.33
Inotrope use 367 (82%) 198 (81%) 0.75
Time of surgery 407(91%) 213(87%) 0.10
Anhepatic phase (Cross clamp) 421(95%) 228(94%) 0.73
Post operative 414(93%) 224(92%) 0.75
Pre-operative
Loop diuretic 172 (38%) 108 (44%) 0.14
Spironolactone 226 (51%) 133 (53%) 0.30
Intra-operative
Albumin (ml) 1059 ± 1311 1199 ± 1509 0.50
Colloid (ml) 2413 ± 2400 2428 ± 3336 0.30
Packed red blood cells (ml) 3440 ± 3281 3974 ± 3758 0.003
Platelets (ml) 813 ± 98 1082 ± 1118 0.0002
Cryoprecipitate (ml) 228 ± 490 212 ± 405 0.90
Fresh frozen plasma (ml) 3695 ± 2759 4582 ± 3121 0.00002
Venovenous bypass 270 (61%) 128 (53%) 0.044
Post-operative
Loop diuretic use 334 (75%) 208 (85%) 0.001
Cyclosporin use 330 (74%) 150 (61%) 0.001
Tacrolimus use 46 (10%) 42 (17%) 0.012
Cyclosporin level, day 1 298 ± 220 269 ± 233 0.09
Cyclosporin level, day 3 816 ± 517 793 ± 548 0.75
Tacrolimus level, day 1 7.8 ± 11.0 6.2 ± 5.3 0.58
Tacrolimus level, day 3 9.2 ± 13.0 15.6 ± 18.0 0.14
Table 4 Univariate analysis of urine output and other
operative variables in patients with and without AKI
NO AKI
(n = 445)
AKI
(n = 243)
p
value
Operative variables
Days on waiting list 149 ± 152 173 ± 206 0.36
Duration of surgery (hrs:
mins)
6:44 ± 1:47 6:46 ± 1.58 0.80
Duration of cross-clamp
(hrs: mins)
1:19 ± 0:35 1:11 ± 0:33 0.004
Urine output (ml)
Surgery start 760 ± 672 810 ± 903 0.40
Cross-clamp 175 ± 186 113 ± 139 0.00001
Post-operative 785 ± 806 811 ± 877 0.60
Table 5 Univariate analysis of intra-operative
hemodynamic factors in patients with and without AKI
NO AKI
(n = 445)
AKI
(n = 243)
p value
Surgery start
Heart rate (beats per minute) 85 ± 15 86 ± 17 0.75
MAP (mm Hg) 75 ± 13 77 ± 13 0.14
CVP (mm Hg) 12.6 ± 5.4 12.7 ± 5.2 0.76
MPAP (mm Hg) 19 ± 5.8 20.6 ± 8.0 0.17
PAWP (mm Hg) 15.3 ± 4.9 16.0 ± 5.3 0.34
CO (L/min) 8.5 ± 3.3 9.7 ± 3.7 0.00001
SV (ml) 101 ± 37 117 ± 72 0.00001
SVR (dynes) 667 ± 279 599 ± 240 0.00002
Cross-clamp
Heart rate (beats per minute) 99.0 ± 17.0 103.0 ± 16.0 0.001
MAP 82.0 ± 12.5 84.0 ± 13.0 0.043
CVP 10.1 ± 5.4 9.3 ± 5.4 0.10
MPAP 14.3 ± 6.3 14.7 ± 7.2 0.87
PAWP 11.8 ± 4.7 11.5 ± 4.4 0.74
CO 6.9 ± 2.4 7.8 ± 7.5 0.23
SV 71.0 ± 26.9 77.8 ± 64.0 0.97
SVR 950.0 ± 415.0 970.0 ± 491.0 0.86
Post-cross-clamp
Heart rate (beats per minute) 98.0 ± 14.0 98.0 ± 15.0 0.50
MAP 74.0 ± 10.6 75.0 ± 10.4 0.50
CVP 12.1 ± 4.6 12.3 ± 4.9 0.60
MPAP 20.0 ± 5.3 21.0 ± 7.1 0.16
PAWP 14.7 ± 4.8 15.3 ± 4.5 0.32
CO 11.0 ± 3.7 12.6 ± 3.7 0.00001
SV 114.0 ± 38.0 134 ± 77 0.00003
SVR 482.0 ± 167.0 432.0 ± 161.0 0.00003
Abbreviations: CO, cardiac output; CVP, central venous pressure; MAP, mean
arterial pressure; MPAP, mean pulmonary artery pressure; PAWP, pulmonary
artery wedge pressure; SV, stroke volume; SVR, systemic vascular resistance.
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We examined the outcome of AKI and NO AKI patients
at 7 days post-OLT. Of the 243 patients who developed
AKI within 2 days of OLT, 3 died, 160 recovered, and 80
still suffered from AKI (53 AKI-1, 3 AKI-2, and 24 AKI-
3). Eight patients received RRT. Of the 445 patients with-
out AKI in the first 2 days post-OLT, 4 died and 291 sub-
sequently developed AKI (77 AKI-1, 13 AKI-2, 60 AKI-
3), with 25 requiring RRT. The etiology and risk factors
for AKI developing > 2 days post-OLT are likely distinct
from those for AKI in the immediate period post-OLT.
Discussion
We performed a retrospective analysis of patients
enrolled in the NIDDK-LTD to identify risk factors for
the development of AKI immediately following OLT
(≤ 48 hours). We examined a variety of demographic,
clinical, and laboratory variables obtained at registration,
pre-OLT, intra-operatively, and after OLT in 688
patients undergoing OLT between April, 1990, and
June, 1994. Our most important finding is that those
patients whose renal function declined while awaiting
OLT, as assessed by an increased SCr or a decreased
eGFR, were at decreased risk for AKI post-OLT. This
seemingly paradoxical result is in contrast to previous
studies, in which pre-OLT renal dysfunction was identi-
fied as a strong predictor of AKI post-OLT. In our ana-
lysis, the absolute level of renal function, as assessed by
125I-iodothalamate clearance, eGFR, SCr, or BUN,
obtained at registration or immediately pre-OLT, did
not differ between patients with and without AKI.
Rather, the change in renal function in the interval from
registration to OLT was the critical determinant
whether OLT recipients developed AKI.
Several considerations bear on the discrepancy
between our results and those of previous studies. The
most important is a previous lack of consensus with
respect to the definition and timing of AKI. Earlier stu-
dies varied widely in the definition and timeframe in
which AKI was studied [12,13]. To circumvent these
issues, we used the AKIN definition of AKI, and limited
our analysis to within 48 hours following OLT.
Table 6 Univariate analysis of measures of renal function in patients with and without AKI
Renal functional parameter NO AKI (n = 445) AKI (n = 243) p value
Iodothalamate clearance (ml/min) (registration) 97 ± 35 105 ± 66 0.44
SCr (mg/dL) (registration) 1.05 ± 0.60 1.05 ± 0.40 0.46
BUN (mg/dL) (registration) 19 ± 18 17 ± 14 0.16
eGFR (ml/min) (registration) 83 ± 31 84 ± 32 0.81
SCr (mg/dL) (pre-operative) 1.19 ± 0.60 1.09 ± 0.40 0.45
BUN (mg/dL) (pre-operative) 19.7 ± 17.0 20.0 ± 15.4 0.66
eGFR (ml/ml) (pre-operative) 76.0 ± 31.0 81.4 ± 33.0 0.058
ΔSCr (mg/dL) 0.13 ± 0.70 0.036 ± 0.390 0.017
ΔBUN (mg/dL) 1.08 ± 23.0 3.05 ± 21.0 0.11
ΔeGFR (ml/min) -7.4 ± 26.0 -2.6 ± 31.0 0.021
% ΔSCr 19 ± 67 9 ± 40 0.014
% ΔBUN 58 ± 170 72 ± 181 0.74
% ΔeGFR -3.7 ± 45.0 3.3 ± 38.0 0.014
ΔSCr/Δt (mg/dL/day) (mg/dL/day) 0.004 ± 0.034 -0.0014 ± 0.015 0.007
ΔBUN/Δt (mg/dL/day) 0.12 ± 1.30 0.166 ± 0.90 0.114
ΔeGFR/Δt (ml/min/day) -0.15 ± 1.29 0.04 ± 0.66 0.006
Abbreviations: BUN, blood urea nitrogen; eGFR, estimated glomerular filtration rate; SCr, serum creatinine.
To convert to S.I. units: multiply BUN by 0.357 (mmol/L); multiply SCr by 88.4 (μmol/L).
Table 7 Multivariate logistic regression analysis of risk factors for the development of all AKI
Variable Regression coefficient SE p value OR 95% CI Coefficient of determination*
Body mass index 0.085 0.02 0.00001 1.09 1.045-1.130 0.070
Childs-Pugh-Turcot score 0.27 0.07 0.00001 1.31 1.15-1.49 0.051
Urine output (cross-clamp) -0.002 0.001 0.003 0.99 0.996-0.990 0.032
ΔSCr/Δt (mg/dL/day) -0.002 0.001 0.019 0.99 0.97-1.00 0.030
Stroke volume (post-operative) 0.006 0.003 0.027 1.006 1.001-1.011 0.015
Race (non-Caucasian) 0.662 0.25 0.008 1.93 1.18-3.10 0.013
Tacrolimus (post-operative) 0.662 0.29 0.022 1.93 1.1-3.4 0.011
* The cumulative coefficient of determination for all variables combined is 0.222.
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Page 6 of 10The issue of timing is subtle but potentially critical.
While AKI can occur anytime following OLT, its etiol-
ogy likely varies with time from surgery. AKI occurring
immediately following OLT and AKI occurring later
during the post-OLT course are probably distinct enti-
ties with distinct predisposing factors and epidemiology.
Moreover, as compared to the general surgical popula-
tion, patients undergoing OLT have both shared and
specific risk factors for AKI [13]. Our interest was in
risk factors specific to OLT. We reasoned that the
shorter the interval between OLT and AKI, the more
likely that AKI would reflect factors particular to OLT.
In addition to issues of timing, most previous studies,
identifying pre-operative renal dysfunction as a risk factor
for AKI, have focused on more severe degrees of renal dys-
function. For example, renal dysfunction pre-OLT has
been defined categorically as a SCr > 1.5 mg/dL, while
AKI post-OLT has been defined as a requirement for RRT
or a doubling of SCr [14-17]. Contreras et al showed that
an elevated pre-OLT SCr was the strongest predictor of
AKI requiring RRT within the first 7 days post-OLT [12].
Similarly, Sanchez et al found that a SCr > 1.9 mg/dL or a
BUN > 27 mg/dL were strong predictors of AKI requiring
RRT, although these authors did not indicate clearly the
timeframe post-OLT that they studied [13].
In contrast, we used continuous measures of renal
function pre-OLT as well as a standardized definition
for post-OLT AKI. To our knowledge, no studies have
evaluated post-OLT AKI by AKIN definitions, and only
two studies have used the RIFLE criteria, on which the
AKIN definitions are based [18]. Like AKIN, RIFLE uses
three categories of graded renal dysfunction (denoted
risk, injury, and failure). Earlier studies using RIFLE cri-
teria offer some support to our conclusions. O’Reardon
Table 8 Categorical analysis of measures of renal function in patients with and without AKI
NO AKI (n = 445) AKI (n = 243) p value OR 95% CI
Increased eGFR 130 (29%) 94 (39%) 0.014 1.53 1.10-2.20
Decreased (or unchanged) eGFR 315 (71%) 149 (61%)
Decreased (or unchanged) SCr 227 (51%) 140 (57%) 0.11 1.30 0.95-1.80
Increased SCr 218 (49%) 103 (43%)
Figure 1 Distribution of rates of change of serum creatinine (ΔSCr/Δtwait) while awaiting orthotopic liver transplantation (OLT) in
patients who did or did not develop post-OLT acute kidney injury (AKI). Patients were stratified in order to according to ΔSCr/Δtwait and
subdivided into deciles containing equal numbers of patients. ΔSCr/Δtwait was defined as the absolute change of serum creatine (ΔSCr) while
awaiting OLT (SCr pre-OLT minus SCr at registration) divided by the time awaiting OLT. The percentage of the total number of patients (n =
243) who developed AKI (AKI) falling within each decile is plotted. Similarly, the percentage of the total number of patients (n = 445) who did
not develop AKI (NO AKI) within each decile is plotted. Negative values of ΔSCr/Δtwait correspond to improved renal function, while positive
values of ΔSCr/Δtwait correspond to worsened renal function. The inverse relationship between degree of renal functional improvement and risk
for AKI was statistically significant (p = 0.008).
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Page 7 of 10et al found that an increased SCr pre-OLT was a risk
factor for the development of renal failure, the most
severe RIFLE category [4]. Notably, an elevation of SCr
pre-OLT was not a risk factor for renal injury, a less
severe RIFLE category. As in our study, patients who
developed renal injury had better pre-operative renal
function, with lower SCr and higher eGFR. It should be
noted, however, that these authors evaluated renal fail-
ure and injury at a later time, namely, two weeks post-
OLT [4]. While Guitard et al, in a retrospective analysis
of 100 OLT patients, also using RIFLE criteria, found
that an elevated SCr pre-OLT was associated with renal
failure by univariate analysis, elevated pre-OLT SCr
dropped out as an independent predictor by multivariate
analysis [18].
Several potential explanations may account for the
apparent protective effect of pre-OLT renal functional
impairment on the development of AKI post-OLT. First,
AKI in these patients may have been masked by an
improvement in renal perfusion, leading to increased
eGFR and decreased SCr. Because OLT reverses many
circulatory abnormalities associated with decreased renal
perfusion [19], patients often recover renal function
post-OLT. It is estimated that a majority of patients
awaiting OLT have some form of reversible renal dys-
function due to diminished renal perfusion [20-23].
Thus, in our study, it is possible that pre-OLT declines
in renal function were reflective of changes in renal per-
fusion rather than intrinsic injury or loss of renal mass.
OLT, by improving renal perfusion and inducing a
decline in SCr and rise in eGFR, could mask small dete-
riorations in renal function consistent with milder stages
of AKI. In accord with this possibility is the fact that an
improvement of renal function was a more powerful
predictor for AKI-2/3 than for AKI-1 (Additional file 1
Tables S2, S3, and S4). Second, consideration should be
given to the possibility that the pre-OLT decline in SCr
among patients developing AKI is dilutional rather than
indicative of improved renal function. While we cannot
formally exclude this possibility, it is noteworthy that
AKI patients sustained a loss, rather than gain, of weight
(14.5 ± 32.0 kg) during the time from registration until
OLT, making it unlikely that their decline of SCr can be
attributed to dilutional effects. Third, the pre-OLT
decline in SCr may reflect a loss of lean body mass, and
it is the debilitation resulting from such a loss of lean
body mass that predisposes to the development of AKI.
Finally, pre-operative declines of renal dysfunction may
truly protect patients from AKI, perhaps via ischemic
preconditioning, as previously described for liver, kidney,
and heart [24-26].
Other independent predictors of AKI post-OLT were
increased BMI, decreased urine output during cross-
clamp, increased post-OLT SV, non-Caucasian race,
post-OLT use of tacrolimus, and Childs Pugh Turcott
score. These factors likely reflect the severity of underly-
ing liver disease (Childs-Pugh-Turcott score and
increased post-OLT SV) and/or degree of renal ischemia
(decreased urine output and post-OLT tacrolimus).
Non-Caucasian race has been identified in other studies
as a risk factor for AKI, for example, among patients
undergoing cardiopulmonary bypass [27,28]. Other stu-
dies have noted an association between tacrolimus and
renal dysfunction [29-32].
An increased BMI was the strongest independent pre-
dictor of AKI post-OLT. A larger BMI may affect dosing
and volume of distribution for drugs with a potential for
nephrotoxicity [33]. Obese patients may have a greater
post-operative inflammatory response with increased
risk of multi-organ dysfunction [34]. In addition,
patients with larger BMI may receive small-for-size
hepatic grafts with resultant graft dysfunction and renal
hypoperfusion [35]. Finally, the possibility exists that a
larger BMI reflects volume overload and profound
ascites, with the observed decline of SCr in AKI patients
being a dilutional effect rather than an indication of
improved renal function. As discussed above, this seems
inlikely, since these patients lost, rather than gained,
considerable weight while awaiting OLT. However, it is
i m p o r t a n tt on o t et h a tt h ed e t e r m i n a t i o no fB M Ii n
patients with ascites is fraught with error, and no for-
mula for BMI in these patients has been validated.
Our study has several strengths. The most important
is our use of the NIDDK-LTD, which contains prospec-
tive data from three centers over a five-year period.
Also, we evaluated risk factors for AKI over a prolonged
timeframe, from registration up to and following OLT.
Finally, we used a very rigorous definition of AKI, as
well as continuous measures of renal function, and we
limited our analysis to the initial 48 hours post-OLT.
Although data on urine output were not available for
the pre- and post-OLT periods, AKI and NO AKI
patients did not differ in relative weight change from
immediately before OLT to either post-OLT day 1 (1.2
± 37.0 kg vs. 1.2 ± 33.0 kg, p = 0.995) or post OLT day
3 (-0.2 ± 37.0 kg vs. -1.4 ± 35.0 kg, p = 0.70). These
data lend support to the notion that the observed differ-
ences in renal outcome post-OLT in AKI vs. NO AKI
patients cannot be attributed to differences in peri-
operative volume status or extent of fluid administra-
tion. Moreover, as discussed above, AKI patients on
average sustained a weight loss of ~14 kg while awaiting
OLT. Indeed, it is noteworthy that SCr decreased
despite a large decrease of weight, of which much was
likely achieved through fluid removal. Taken together,
the observed pre-OLT decrease of SCr among AKI
patients would seem to be independent of dilutional
factors.
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Page 8 of 10We note the following limitations to our study. First, we
were unable to determine the etiology of renal dysfunction
in our patients. The distinction between prerenal and
renal causes of renal dysfunction pre-OLT may impact on
the interpretation and significance of improved renal func-
tion as a risk factor for AKI post-OLT.
Third, we used the MDRD formula to determine
eGFR. Estimates of renal function in cirrhotic patients
that are based on SCr are known to overestimate the
true GFR. However, it is important to emphasize that
our analysis was limited to the correlation between
changes (not absolute levels) of eGFR and the develop-
ment of AKI following OLT.
Finally, although we included MELD scores in our
analysis, our patients came from the pre-MELD era, and
risk factors for AKI may differ in the current era, in
which patients undergo OLT with more severe renal
function. In the last two decades, there have been medi-
cal and surgical advances in the management of patients
undergoing OLT. These include caval sparing, split liver
transplants, diminished usage of veno-veno bypass,
shorter anhepatic times, improved anesthetic techniques,
and strategies to minimize calcineurin exposure [36-38].
These improvements, while decreasing the risk for AKI
during OLT, are counterbalanced by two factors, which
simultaneously increase the risk for AKI: transplantation
of patients with higher MELD scores, and expansion of
the donor pool to include non-heart-beating and
“expanded-criteria donors [39-41].” With those caveats
in mind, we believe that the impact of pre-operative
changes in renal function on the risk for peri-operative
OLT AKI is a reflection of the cirrhotic hemodynamic
milieu per se, rather than any specific level of hepatic
dysfunction, as indicated by the MELD score. In addi-
tion, our results may have a more general relevance and
extend to surgical procedures other than OLT in
patients with end stageliver disease. Analysis of newer
databases should help to resolve both of these points.
Conclusion
In summary, our study is the largest to date on the
development of AKI post-OLT using AKIN definitions.
Our most important finding is that the absolute level of
renal function pre-OLT was not a risk factor for AKI
post-OLT. Rather, patients whose renal function
declined while awaiting OLT were protected from AKI.
This finding may represent true protection, via perhaps
ischemic pre-conditioning, or represent a masking of
milder forms of AKI, via correction of the cirrhotic
milieu and improved renal perfusion. Irrespective of
mechanism, the seemingly paradoxical result that declin-
ing renal function identifies patients at lesser risk for
AKI post-OLT underscores the complex interrelation-
ship between liver and kidney disease. Given the scarcity
of organs available for simultaneous liver-kidney trans-
plant, there is a need for additional prospective studies,
which might include an analysis of peri-OLT kidney
biopsies as part of the study protocol, to dileneate the
impact of pre-OLT renal dysfunction following OLT.
Our study suggests that not only the etiology but also
t h ec o u r s eo fo fp r e - O L Tr e n a ld y s f u n c t i o nm a yp l a ya
critical role.
Additional material
Additional file 1: Supplemental tables. Word DOC containing Table S1,
S2, S3 and S4
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